Cargando…
Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study
BACKGROUND: De novo combination of lamivudine (Lam) and adefovir (Adv) was not rarely used in clinical practice. However, head-to-head comparisons of entecavir (Etv) monotherapy with this combination in hepatitis B virus (HBV)-related compensated cirrhosis patients are unavailable. This study aimed...
Autores principales: | Wu, Xiaoning, Zhou, Jialing, Xie, Wen, Ding, Huiguo, Ou, Xiaojuan, Chen, Guofeng, Ma, Anlin, Xu, Xiaoyuan, Ma, Hui, Xu, Youqing, Liu, Xiaoqing, Meng, Tongtong, Wang, Lin, Sun, Yameng, Wang, Bingqiong, Kong, Yuanyuan, Ma, Hong, You, Hong, Jia, Jidong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448536/ https://www.ncbi.nlm.nih.gov/pubmed/31015765 http://dx.doi.org/10.2147/IDR.S185120 |
Ejemplares similares
-
Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety
por: Lian, Jiang-Shan, et al.
Publicado: (2019) -
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
por: Sheng, Yun-Jian, et al.
Publicado: (2011) -
De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
por: Yang, Song, et al.
Publicado: (2016) -
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients
por: Wu, Xiaoning, et al.
Publicado: (2023) -
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)